Young Joo Lee

Young Joo Lee

Auto-generated profile, based on publicly available information

Young Joo Lee

Division of Breast Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
DKDongyoung Kim
Dongyoung Kim
HWHyun-Kyung Woo
Hyun-Kyung Woo
CLChaeeun Lee
Chaeeun Lee
YMYoohong Min
Yoohong Min
SKSumit Kumar
Sumit Kumar
YCYoon-Kyoung Cho
Yoon-Kyoung Cho

1 January 2023 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
YLYoung Joo Lee
Young Joo Lee
SJSeung Pil Jung
Seung Pil Jung
JBJeoung Won Bae
Jeoung Won Bae
SYSun Moon Yang
Sun Moon Yang
JYJi Young You
Ji Young You
SBSoo Youn Bae
Soo Youn Bae
Lee YJ, et al. Ann Surg Treat Res. 2023 Jan;104(1):1-9. https://doi.org/10.4174/astr.2023.104.1.1

3 December 2025 in Nature
Verified
Journal Article
Open access
PDF file
RKRyul Kim
Ryul Kim
JYJonghan Yu
Jonghan Yu
JLJoonoh Lim
Joonoh Lim
BOBrian Baek-Lok Oh
Brian Baek-Lok Oh
SNSeok Jin Nam
Seok Jin Nam
Yeon Hee 박연희 ParkYeon Hee 박연희 Park
Yeon Hee 박연희 Park
Breast cancer remains a major global health challenge1. Here, to comprehensively characterize its genomic landscape and the clinical significance of genomic characteristics, we analysed whole-genome sequences from 1,364 clinically annotated breast cancers, with transcriptome data available for most cases. Our study expands the repertoire of oncogenic alterations and identifies novel driver genes, recurrent gene fusions, structural variants and copy number alterations. Timing analyses on copy number alterations suggest that genomic instability emerges decades before tumour diagnosis, and offer insights into early initiation of tumorigenesis. Pattern-driven genomic features, including mutational signatures2, homologous recombination deficiency3, tumour mutational burden and tumour heterogeneity scores4, were associated with clinical outcomes, highlighting their potential utility as predictive biomarkers for clinical evaluation of treatments such as CDK4/6 and HER2 inhibitors, as well as adjuvant and neoadjuvant chemotherapy. These findings highlight the power of large-scale, clinically annotated whole-genome sequencing in advancing our understanding of how genomic alterations shape patient outcomes.

1 January 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JRJai Min Ryu
Jai Min Ryu
HCHee Jun Choi
Hee Jun Choi
EPEunhwa Park
Eunhwa Park
JKJi Young Kim
Ji Young Kim
YLYoung Joo Lee
Young Joo Lee
KSKorean Breast Cancer Society
Korean Breast Cancer Society
Ryu JM, et al. J Breast Cancer. 2022 Apr;25(2):94-105. https://doi.org/10.4048/jbc.2022.25.e17

6 January 2020 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
HKHyun-Ki Kim
Hyun-Ki Kim
ELEun Jin Lee
Eun Jin Lee
YLYoung-Jae Lee
Young-Jae Lee
JKJisun Kim
Jisun Kim
YKYongsub Kim
Yongsub Kim
SASei-Hyun Ahn
Sei-Hyun Ahn

5 August 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
PPPill Sun Paik
Pill Sun Paik
JCJung Eun Choi
Jung Eun Choi
SLSeok Won Lee
Seok Won Lee
YLYoung Joo Lee
Young Joo Lee
YKYoung-Joon Kang
Young-Joon Kang
KSKorean Breast Cancer Society
Korean Breast Cancer Society